Clinical trials
Phase 2 Surgical Wound Infection trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
21 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 5 |
| 2015 | 2 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 12 |
| Unknown status | 6 |
| Terminated | 3 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Cancer Center, Korea | 2 |
| Zurex Pharma, Inc. | 2 |
| Ain Shams Maternity Hospital | 1 |
| Angela Bianco | 1 |
| Attabib, Najmedden, M.D. | 1 |
| Destiny Pharma Plc | 1 |
| Dr. Promise Tamunoipiriala Jaja | 1 |
| Dr. Reddy's Laboratories Limited | 1 |
| Federal University of São Paulo | 1 |
| First Affiliated Hospital, Sun Yat-Sen University | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Surgical Wound Infection | 21 |
| Cross Infection | 3 |
| Colorectal Neoplasms | 2 |
| Staphylococcal Infections | 2 |
| Stomach Neoplasms | 2 |
| Wound Infection | 2 |
| Diverticulum | 1 |
| Gastrointestinal Stromal Tumors | 1 |
| Infections | 1 |
| Inflammatory Bowel Diseases | 1 |
Trials
Showing 26 to 21 of 21. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.